Adrienne C. Lahti

2 papers in the library · 444 citations · publishing 1995-2026

Papers

Ketamine activates psychosis and alters limbic blood flow in schizophrenia

Neuroreport April 1, 1995 Adrienne C. Lahti, Henry H. Holcomb, Deborah R. Medoff et al. 440 citations

A subanesthetic dose of the NMDA antagonist ketamine temporarily activated psychotic symptoms in people with schizophrenia, closely resembling their usual episodes. In a PET study using radioactive water, ketamine increased blood flow in the anterior cingulate cortex and decreased flow in the hippocampus and primary visual cortex. These findings support the idea that altered glutamate transmission may contribute to schizophrenia and PCP-induced psychosis.

DOI: 10.1097/00001756-199504190-00011

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara Lappan, Richard C. Shelton et al. 4 citations

A single 25 mg dose of psilocybin, combined with psychotherapy, led to a higher percentage of cocaine-abstinent days, a greater likelihood of complete abstinence, and a longer time before the first cocaine lapse over 180 days compared with an active placebo (100 mg diphenhydramine) in a randomized, quadruple-blind trial. Among 40 participants with cocaine use disorder, 33 were men, 33 were Black, and most had low income. Psilocybin appeared safe, with no serious adverse events, and may offer a treatment for cocaine use disorder in underrepresented populations.

DOI: 10.1001/jamanetworkopen.2026.11029 Psilocybin Abstinence Cocaine dependence Cocaine use +9